Literature DB >> 22247247

Intestinal failure-associated liver disease in hospitalised children.

Judith Pichler1, Venetia Horn, Sarah Macdonald, Susan Hill.   

Abstract

OBJECTIVE AND AIM: Liver disease is a potentially life-threatening complication of intravenous/parenteral nutrition (PN). Our aim was to determine the incidence, aetiology and outcome of intestinal failure-associated liver disease (IFALD) in hospitalised children treated with long-term PN (>27 days).
METHODS: Over 4 years all long-term intestinal failure (IF) patients were reviewed for the possible predisposing factors of age, diagnosis, PN lipid, sepsis, length of PN treatment and length of hospitalisation. Outcome measures were IFALD incidence, severity and prognosis.
RESULTS: Of 60/279 (22%) children aged 0-18 years who developed IFALD, 13 (5%) progressed to type 3/end stage disease. IFALD was associated with younger age (p=0.03), longer treatment (p<0.001), longer hospitalisation (p=0.01), surgical diagnosis (p=0.005) and prematurity (p=0.03). IFALD was not associated with sepsis. Intestinal surgery was associated with IFALD independently of age (p=0.03). Survival was 86%, with three deaths attributed to IFALD (1% of all cases), all of which were surgical.
CONCLUSION: IFALD incidence was lower than previously reported in paediatric patients, with surgical neonates at greatest risk.

Entities:  

Mesh:

Year:  2012        PMID: 22247247     DOI: 10.1136/archdischild-2011-300274

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  15 in total

Review 1.  New Insights Into Intestinal Failure-Associated Liver Disease in Children.

Authors:  Racha T Khalaf; Ronald J Sokol
Journal:  Hepatology       Date:  2020-03-18       Impact factor: 17.425

2.  An Observational Study of Smoflipid vs Intralipid on the Evolution of Intestinal Failure-Associated Liver Disease in Infants With Intestinal Failure.

Authors:  Christina Belza; John C Wales; Glenda Courtney-Martin; Nicole de Silva; Yaron Avitzur; Paul W Wales
Journal:  JPEN J Parenter Enteral Nutr       Date:  2019-08-25       Impact factor: 4.016

3.  Intestinal Microbiota, Lipids, and the Pathogenesis of Intestinal Failure-Associated Liver Disease.

Authors:  Way Seah Lee; Ronald J Sokol
Journal:  J Pediatr       Date:  2015-06-27       Impact factor: 4.406

4.  Short bowel syndrome in infancy: recent advances and practical management.

Authors:  Elena Cernat; Chloe Corlett; Natalia Iglesias; Nkem Onyeador; Julie Steele; Akshay Batra
Journal:  Frontline Gastroenterol       Date:  2020-12-16

5.  Partially hydrolyzed guar gum alleviates hepatic steatosis and alters specific gut microbiota in a murine liver injury model.

Authors:  Takayuki Fujii; Haruyuki Nakayama-Imaohji; Aya Tanaka; Hiroto Katami; Kazuya Tanaka; Yoichi Chiba; Machi Kawauchi; Masaki Ueno; Tomomi Kuwahara; Ryuichi Shimono
Journal:  Pediatr Surg Int       Date:  2022-09-12       Impact factor: 2.003

Review 6.  Dilemmas in feeding infants with intestinal failure: a neonatologist's perspective.

Authors:  Amy B Hair; Misty Good
Journal:  J Perinatol       Date:  2022-09-20       Impact factor: 3.225

7.  Comparison of liver function with two new/mixed intravenous lipid emulsions in children with intestinal failure.

Authors:  J Pichler; V Simchowitz; S Macdonald; S Hill
Journal:  Eur J Clin Nutr       Date:  2014-06-25       Impact factor: 4.016

8.  Pediatric intestinal failure-associated liver disease is reversed with 6 months of intravenous fish oil.

Authors:  Kara L Calkins; James C Y Dunn; Stephen B Shew; Laurie Reyen; Douglas G Farmer; Sherin U Devaskar; Robert S Venick
Journal:  JPEN J Parenter Enteral Nutr       Date:  2013-07-26       Impact factor: 4.016

9.  Prevention and treatment of intestinal failure-associated liver disease in children.

Authors:  Bram P Raphael; Christopher Duggan
Journal:  Semin Liver Dis       Date:  2013-02-08       Impact factor: 6.115

Review 10.  Prevention and Treatment of Intestinal Failure-Associated Liver Disease in Children.

Authors:  Lorenzo Norsa; Emanuele Nicastro; Angelo Di Giorgio; Florence Lacaille; Lorenzo D'Antiga
Journal:  Nutrients       Date:  2018-05-24       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.